Expert Perspectives: Sequencing Approaches with CAR-T and Bispecifics in R/R MM

Opinion
Video

The expert panel shares clinical insights on sequencing CAR T-cell therapies and bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content